Regular articleDetection of BRAF p.V600E Mutations in Melanomas: Comparison of Four Methods Argues for Sequential Use of Immunohistochemistry and Pyrosequencing
Cited by (0)
Supported by grants from the nonprofit associations Ligue contre le Cancer, AREP (Association Pour la Recherche de l’Enseignement en Pathologie), and AROLD (Association Pour la Recherche en Oncologie Digestive).
Disclosures: J.F.E. and P.S. received honoraria for counseling on diagnosis and/or treatment of patients with melanomas from Roche and Glaxo Smith Kline. D.C. and A.V.D. applied for a patent on the diagnostic use of BRAF p.V600E mutant–specific antibody VE1. All terms are being managed by the German Cancer Research Center in accordance with its conflict of interest policies. Funding sources had no involvement in study design, data collection, data analysis, data interpretation, writing of the manuscript, approval of the manuscript, or the decision to submit the manuscript for publication. No one has been paid to write this article by a pharmaceutical company or other agency.